BioCentury
ARTICLE | Clinical News

Betmiga mirabegron regulatory update

May 20, 2013 7:00 AM UTC

The U.K.'s NICE issued final appraisal determination (FAD) recommending Betmiga mirabegron from Astellas for the symptomatic treatment of overactive bladder (OAB) only in patients for whom antimuscarinic drugs are not suitable. The committee concluded that the effectiveness of Betmiga is similar to that of antimuscarinic drugs and that it appears to have a different side-effect profile. However, NICE said there is uncertainty about the differences in costs and effects between drugs and the incremental cost-effectiveness ratios (ICER) are therefore unstable. The FAD is in line with draft guidance issued in March (see BioCentury, March 4). ...